Are Ergothioneine Levels in Blood Associated with Chronic Peripheral Neuropathy in Colorectal Cancer Patients Who Underwent Chemotherapy?

References

• American Cancer Society: Colorectal Cancer: Facts and Figures 2017–2019. Atlanta: American Cancer Society, 2017.
   Google Scholar
• Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, and Kalofonos HP: A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 34, 368–377, 2008.
   PubMed Web of Science ®Google Scholar
• Beijers AJ, Mols F, Tjan-Heijnen VC, Faber CG, van de Poll-Franse LV, et al.: Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry. Acta Oncol 54, 463–469, 2015.
   PubMed Web of Science ®Google Scholar
• Ocean AJ, and Vahdat LT: Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 12, 619–625, 2004.
   PubMed Web of Science ®Google Scholar
• Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, et al.: Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. PAIN^® 155, 2461–2470, 2014.
   PubMed Web of Science ®Google Scholar
• von Hehn CA, Baron R, and Woolf CJ: Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron 73, 638–652, 2012.
   PubMed Web of Science ®Google Scholar
• Derksen TM, Bours MJ, Mols F, and Weijenberg MP: Lifestyle-related factors in the self-management of chemotherapy-induced peripheral neuropathy in colorectal cancer: a systematic review. Evid Based Complem Alternat Med 2017, 7916031, 2017.
   PubMed Web of Science ®Google Scholar
• Jong NN, Nakanishi T, Liu JJ, Tamai I, and McKeage MJ: Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons. J Pharmacol Exp Ther 338, 537–547, 2011.
   PubMed Web of Science ®Google Scholar
• Song T-Y, Chen C-L, Liao J-W, Ou H-C, and Tsai M-S: Ergothioneine protects against neuronal injury induced by cisplatin both in vitro and in vivo. Food Chem Toxicol 48, 3492–3499, 2010.
   PubMed Web of Science ®Google Scholar
• Nishida K, Takeuchi K, Hosoda A, Sugano S, Morisaki E, et al. Ergothioneine ameliorates oxaliplatin-induced peripheral neuropathy in rats. Life Sci 207, 516–524, 2018.
   PubMed Web of Science ®Google Scholar
• Cheah IK, and Halliwell B: Ergothioneine; antioxidant potential, physiological function and role in disease. Biochim Biophys Acta 1822, 784–793, 2012.
   PubMed Web of Science ®Google Scholar
• Kalaras MD, Richie JP, Calcagnotto A, and Beelman RB: Mushrooms: a rich source of the antioxidants ergothioneine and glutathione. Food Chem 233, 429–433, 2017.
   PubMed Web of Science ®Google Scholar
• Ey J, Schomig E, and Taubert D: Dietary sources and antioxidant effects of ergothioneine. J Agric Food Chem 55, 6466–6474, 2007.
   PubMed Web of Science ®Google Scholar
• Halliwell B, Cheah IK, and Drum CL: Ergothioneine, an adaptive antioxidant for the protection of injured tissues? A hypothesis. Biochem Biophys Res Commun 470, 245–250, 2016.
   PubMed Web of Science ®Google Scholar
• Grundemann D: The ergothioneine transporter controls and indicates ergothioneine activity – a review. Prev Med 54, S71–S74, 2012.
   PubMed Web of Science ®Google Scholar
• Fujita S, Hirota T, Sakiyama R, Baba M, and Ieiri I: Identification of drug transporters contributing to oxaliplatin-induced peripheral neuropathy. J Neurochem 148, 373–385, 2019.
   PubMed Web of Science ®Google Scholar
• Ta LE, Espeset L, Podratz J, and Windebank AJ: Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 27, 992–1002, 2006.
   PubMed Web of Science ®Google Scholar
• Winkels RM, Heine-Bröring RC, Van Zutphen M, van Harten-Gerritsen S, Kok DE, et al.: The COLON study: Co lorectal cancer: L ongitudinal, O bservational study on N utritional and lifestyle factors that may influence colorectal tumour recurrence, survival and quality of life. BMC Cancer 14, 374, 2014.
   PubMed Web of Science ®Google Scholar
• Smith EML, Barton DL, Qin R, Steen PD, Aaronson NK, et al.: Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res 22, 2787–2799, 2013.
   PubMed Web of Science ®Google Scholar
• Lehky T, Leonard G, Wilson R, Grem J, and Floeter M: Oxaliplatin‐induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29, 387–392, 2004.
   PubMed Web of Science ®Google Scholar
• Saif MW, Syrigos K, Kaley K, and Isufi I: Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res 30, 2927–2933, 2010.
   PubMed Web of Science ®Google Scholar
• Park SB, Goldstein D, Krishnan AV, Lin CSY, Friedlander ML, et al.: Chemotherapy‐induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 63, 419–437, 2013.
   PubMed Web of Science ®Google Scholar
• Mols F, van de Poll-Franse LV, Vreugdenhil G, Beijers AJ, Kieffer JM, et al.: Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population. Eur J Cancer 69, 28–38, 2016.
   PubMed Web of Science ®Google Scholar
• Feunekes IJ, Van Staveren WA, Graveland F, De Vos J, and Burema J: Reproducibility of a semiquantitative food frequency questionnaire to assess the intake of fats and cholesterol in The Netherlands. Int J Food Sci Nutr. 46, 117–123, 1995.
   PubMed Web of Science ®Google Scholar
• Verkleij-Hagoort AC, de Vries JH, Stegers MP, Lindemans J, Ursem NT, et al.: Validation of the assessment of folate and vitamin B12 intake in women of reproductive age: the method of triads. Eur J Clin Nutr 61, 610–615, 2007.
   PubMed Web of Science ®Google Scholar
• Siebelink E, Geelen A, and de Vries JH: Self-reported energy intake by FFQ compared with actual energy intake to maintain body weight in 516 adults. Br J Nutr 106, 274–281, 2011.
   PubMed Web of Science ®Google Scholar
• Tamhane AR, Westfall AO, Burkholder GA, and Cutter GR: Prevalence odds ratio versus prevalence ratio: choice comes with consequences. Stat Med 35, 5730–5735, 2016.
   PubMed Web of Science ®Google Scholar
• Zeng L, Alongkronrusmee D, and van Rijn RM: An integrated perspective on diabetic, alcoholic, and drug-induced neuropathy, etiology, and treatment in the US. J Pain Res 10, 219, 2017.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, et al. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 46, 479–494, 2010.
   PubMed Web of Science ®Google Scholar
• Kieffer JM, Postma TJ, van de Poll-Franse L, Mols F, Heimans JJ, et al. Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20). Qual Life Res 26, 2999–3010, 2017.
   PubMed Web of Science ®Google Scholar
• Zhang S, Tomata Y, Sugiyama K, Sugawara Y, and Tsuji I: Mushroom consumption and incident Dementia in Elderly Japanese: The Ohsaki Cohort 2006 Study. J Am Geriatr Soc 65, 1462–1469, 2017.
   PubMed Web of Science ®Google Scholar
• Baars JJP, and Sonnenberg ASM: Voedingswaarden Champignons en Andere Paddenstoelen. Wageningen: Plant Research International B.V., 2008.
   Google Scholar
• Royse DJ, (ed.): A global perspective on the high five: Agaricus, Pleurotus, Lentinula, Auricularia & Flammulina. In Proceedings of the 8th International Conference on Mushroom Biology and Mushroom Products. India: ICAR-Directorate of Mushroom Research, 2014.
   Google Scholar
• Ma J, Kavelaars A, Dougherty PM, and Heijnen CJ: Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy: Targeting the source. Cancer 124, 2289–2298, 2018.
   PubMed Web of Science ®Google Scholar
• Brami C, Bao T, and Deng G: Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review. Crit Rev Oncol Hematol 98, 325–334, 2016.
   PubMed Web of Science ®Google Scholar
• Schloss JM, Colosimo M, Airey C, Masci PP, Linnane AW, and Vitetta L: Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review. Clin Nutr 32, 888–893, 2013.
   PubMed Web of Science ®Google Scholar
• Maestri A, De Pasquale Ceratti A, Cundari S, Zanna C, Cortesi E, et al.: A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 91, 135–138, 2005.
   PubMed Web of Science ®Google Scholar
• Bianchi G, Vitali G, Caraceni A, Ravaglia S, Capri G, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-l-carnitine. Eur J Cancer 41, 1746–1750, 2005.
   PubMed Web of Science ®Google Scholar
• Pace A, Giannarelli D, Galie E, Savarese A, Carpano S, et al. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology 74, 762–766, 2010.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Chroni E, Koutras A, Iconomou G, Papapetropoulos S, et al. A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support Care Cancer 14, 1134–1140, 2006.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 31, 2627–2633, 2013.
   PubMed Web of Science ®Google Scholar
• Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy BP, et al. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer 19, 1769–1777, 2011.
   PubMed Web of Science ®Google Scholar